Published in Cancer Cell on October 18, 2011
Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov (2012) 2.76
Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene (2013) 2.64
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci Transl Med (2015) 2.55
Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. J Biol Chem (2012) 2.25
Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol (2014) 2.23
Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res (2014) 2.15
Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene (2013) 1.86
TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. Proc Natl Acad Sci U S A (2013) 1.77
Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene (2013) 1.67
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer (2015) 1.55
ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells. Clin Cancer Res (2015) 1.50
Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. Endocr Relat Cancer (2014) 1.45
Molecular antagonism between X-chromosome and autosome signals determines nematode sex. Genes Dev (2013) 1.43
Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Res (2012) 1.40
ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. J Clin Invest (2013) 1.38
The androgen/androgen receptor axis in prostate cancer. Curr Opin Oncol (2012) 1.29
Androgen receptor-independent function of FoxA1 in prostate cancer metastasis. Cancer Res (2013) 1.26
Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation. EMBO Mol Med (2013) 1.23
Androgen receptor antagonists in castration-resistant prostate cancer. Cancer J (2013) 1.19
Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov (2013) 1.18
Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit. Clin Cancer Res (2013) 1.13
Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation. J Biol Chem (2012) 1.13
Regulation of several androgen-induced genes through the repression of the miR-99a/let-7c/miR-125b-2 miRNA cluster in prostate cancer cells. Oncogene (2013) 1.12
CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor. Oncogene (2013) 1.12
Androgen receptor splice variants in the era of enzalutamide and abiraterone. Horm Cancer (2014) 1.11
Adaptation or selection--mechanisms of castration-resistant prostate cancer. Nat Rev Urol (2012) 1.10
Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer. Nucleic Acids Res (2014) 1.05
Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. Sci Signal (2014) 1.03
Decoding the androgen receptor splice variants. Transl Androl Urol (2013) 1.01
GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex. Proc Natl Acad Sci U S A (2014) 1.01
The stress response mediator ATF3 represses androgen signaling by binding the androgen receptor. Mol Cell Biol (2012) 0.98
Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. Hum Mol Genet (2015) 0.96
LncRNA HOTAIR Enhances the Androgen-Receptor-Mediated Transcriptional Program and Drives Castration-Resistant Prostate Cancer. Cell Rep (2015) 0.96
Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer. Oncogene (2015) 0.95
Overcoming drug resistance and treating advanced prostate cancer. Curr Drug Targets (2012) 0.95
Triazole-dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration. J Med Chem (2013) 0.94
Coregulator control of androgen receptor action by a novel nuclear receptor-binding motif. J Biol Chem (2014) 0.94
Whole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate cancer. Mol Cancer Res (2014) 0.94
Targeting the adaptive molecular landscape of castration-resistant prostate cancer. EMBO Mol Med (2015) 0.93
Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity. Cell Rep (2014) 0.93
Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. J Natl Cancer Inst (2015) 0.92
The emerging role of histone lysine demethylases in prostate cancer. Mol Cancer (2012) 0.91
GEMMs shine a light on resistance to androgen deprivation therapy for prostate cancer. Cancer Cell (2013) 0.90
The steroid receptor coactivator-3 is required for the development of castration-resistant prostate cancer. Cancer Res (2013) 0.89
Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells. Int J Biochem Cell Biol (2014) 0.89
The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer. Mol Oncol (2013) 0.89
Tyrosine kinase BMX phosphorylates phosphotyrosine-primed motif mediating the activation of multiple receptor tyrosine kinases. Sci Signal (2013) 0.88
Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. Oncotarget (2013) 0.88
Crosstalk between nuclear MET and SOX9/β-catenin correlates with castration-resistant prostate cancer. Mol Endocrinol (2014) 0.87
Expression of androgen receptor splice variants in clinical breast cancers. Oncotarget (2015) 0.85
Human α(2)β(1)(HI) CD133(+VE) epithelial prostate stem cells express low levels of active androgen receptor. PLoS One (2012) 0.85
Androgen receptor functions in prostate cancer development and progression. Asian J Androl (2014) 0.85
Interrogating genomic and epigenomic data to understand prostate cancer. Biochim Biophys Acta (2012) 0.85
Constitutive activity of the androgen receptor. Adv Pharmacol (2014) 0.84
Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC). BMC Urol (2014) 0.84
Epigenetic mechanisms in commonly occurring cancers. DNA Cell Biol (2012) 0.84
KDM1 class flavin-dependent protein lysine demethylases. Biopolymers (2015) 0.84
Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. Prostate Cancer Prostatic Dis (2016) 0.83
Catalog of mRNA expression patterns for DNA methylating and demethylating genes in developing mouse lower urinary tract. Gene Expr Patterns (2013) 0.82
Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival. Oncogene (2015) 0.82
Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine (2016) 0.82
Modeling truncated AR expression in a natural androgen responsive environment and identification of RHOB as a direct transcriptional target. PLoS One (2012) 0.82
Inhibition of hedgehog and androgen receptor signaling pathways produced synergistic suppression of castration-resistant prostate cancer progression. Mol Cancer Res (2013) 0.81
Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression. Oncotarget (2015) 0.81
Tumor expression of adiponectin receptor 2 and lethal prostate cancer. Carcinogenesis (2015) 0.81
Glycosylation is an Androgen-Regulated Process Essential for Prostate Cancer Cell Viability. EBioMedicine (2016) 0.81
Polycomb-mediated disruption of an androgen receptor feedback loop drives castration-resistant prostate cancer. Cancer Res (2016) 0.80
A hormone-dependent feedback-loop controls androgen receptor levels by limiting MID1, a novel translation enhancer and promoter of oncogenic signaling. Mol Cancer (2014) 0.80
The biology of castration-resistant prostate cancer. Curr Probl Cancer (2014) 0.80
The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer Cells. J Biol Chem (2015) 0.79
FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer. Oncotarget (2015) 0.79
Androgen receptor genomic regulation. Transl Androl Urol (2013) 0.79
Assembly of methylated KDM1A and CHD1 drives androgen receptor-dependent transcription and translocation. Nat Struct Mol Biol (2016) 0.79
CCAAT/Enhancer binding protein β controls androgen-deprivation-induced senescence in prostate cancer cells. Oncogene (2015) 0.78
Negative regulation of the androgen receptor gene through a primate-specific androgen response element present in the 5' UTR. Horm Cancer (2014) 0.78
Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia. Ther Adv Hematol (2015) 0.78
AR-v7 protein expression is regulated by protein kinase and phosphatase. Oncotarget (2015) 0.78
BAP18 coactivates androgen receptor action and promotes prostate cancer progression. Nucleic Acids Res (2016) 0.78
Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms. Oncogene (2016) 0.78
NANOG reprograms prostate cancer cells to castration resistance via dynamically repressing and engaging the AR/FOXA1 signaling axis. Cell Discov (2016) 0.77
The interplay between the lysine demethylase KDM1A and DNA methyltransferases in cancer cells is cell cycle dependent. Oncotarget (2016) 0.77
New targets for resistant prostate cancer. Oncotarget (2014) 0.77
Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer. Oncotarget (2016) 0.77
Androgen receptor epigenetics. Transl Androl Urol (2013) 0.77
FOXA1 acts upstream of GATA2 and AR in hormonal regulation of gene expression. Oncogene (2016) 0.77
Protein phosphatase 1 suppresses androgen receptor ubiquitylation and degradation. Oncotarget (2016) 0.76
Proline-Directed Androgen Receptor Phosphorylation. J Mol Genet Med (2013) 0.76
Agonist-specific Protein Interactomes of Glucocorticoid and Androgen Receptor as Revealed by Proximity Mapping. Mol Cell Proteomics (2017) 0.75
TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer. Prostate Cancer Prostatic Dis (2017) 0.75
The Androgen Receptor and VEGF: Mechanisms of Androgen-Regulated Angiogenesis in Prostate Cancer. Cancers (Basel) (2017) 0.75
Inhibition of androgen receptor by decoy molecules delays progression to castration-recurrent prostate cancer. PLoS One (2017) 0.75
Inhibition of AKR1C3 activation overcomes resistance to abiraterone in advanced prostate cancer. Mol Cancer Ther (2016) 0.75
Androgen receptor regulates SRC expression through microRNA-203. Oncotarget (2016) 0.75
Scaffold attachment factor B2 (SAFB2)-null mice reveal non-redundant functions of SAFB2 compared with its paralog, SAFB1. Dis Model Mech (2015) 0.75
LSD1 binds to HPV16 E7 and promotes the epithelial-mesenchymal transition in cervical cancer by demethylating histones at the Vimentin promoter. Oncotarget (2016) 0.75
One-Carbon Metabolism in Prostate Cancer: The Role of Androgen Signaling. Int J Mol Sci (2016) 0.75
Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer. Cancers (Basel) (2017) 0.75
Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy. Cancers (Basel) (2017) 0.75
Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes. BMC Cancer (2016) 0.75
Low β2-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism. Oncotarget (2016) 0.75
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell (2004) 21.30
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87
LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature (2005) 8.53
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol (2004) 6.95
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell (2010) 6.76
In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet (1995) 6.60
Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med (1995) 6.26
A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell (2007) 5.99
Histone methylation-dependent mechanisms impose ligand dependency for gene activation by nuclear receptors. Cell (2007) 4.45
Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res (2001) 4.12
Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol (2007) 3.89
VCaP, a cell-based model system of human prostate cancer. In Vivo (2001) 3.36
Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol (2009) 3.11
The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest (2010) 3.09
DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression. Science (2008) 3.09
Phosphorylation of histone H3 at threonine 11 establishes a novel chromatin mark for transcriptional regulation. Nat Cell Biol (2007) 2.50
Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Cancer Res (2006) 2.46
Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol (2008) 2.35
Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4. Nature (2010) 2.01
Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol (1994) 1.94
Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Res (2009) 1.76
Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol (2009) 1.75
Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones. J Biol Chem (1992) 1.73
Identification of the major oxidative 3alpha-hydroxysteroid dehydrogenase in human prostate that converts 5alpha-androstane-3alpha,17beta-diol to 5alpha-dihydrotestosterone: a potential therapeutic target for androgen-dependent disease. Mol Endocrinol (2005) 1.63
Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci U S A (1996) 1.61
Novel binding of HuR and poly(C)-binding protein to a conserved UC-rich motif within the 3'-untranslated region of the androgen receptor messenger RNA. J Biol Chem (2002) 1.57
Autologous down-regulation of androgen receptor messenger ribonucleic acid. Mol Endocrinol (1990) 1.40
Development of the VCaP androgen-independent model of prostate cancer. Urol Oncol (2006) 1.33
Androgen increases androgen receptor protein while decreasing receptor mRNA in LNCaP cells. Mol Cell Endocrinol (1991) 1.18
Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor. Mol Endocrinol (2002) 1.17
Androgen receptor overexpression in prostate cancer linked to Pur alpha loss from a novel repressor complex. Cancer Res (2008) 1.10
Transcriptional regulation of androgen receptor gene expression in Sertoli cells and other cell types. Mol Cell Endocrinol (1992) 1.08
Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line. Oncogene (2004) 1.04
Identification and characterization of a suppressor element in the 5'-flanking region of the mouse androgen receptor gene. Nucleic Acids Res (1994) 0.94
Regulation of androgen receptor protein and mRNA concentrations by androgens in rat ventral prostate and seminal vesicles and in human hepatoma cells. Mol Endocrinol (1990) 0.84
Model-based analysis of ChIP-Seq (MACS). Genome Biol (2008) 51.63
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
Genome-wide analysis of estrogen receptor binding sites. Nat Genet (2006) 18.63
Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell (2005) 14.32
FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell (2008) 14.18
Model-based analysis of tiling-arrays for ChIP-chip. Proc Natl Acad Sci U S A (2006) 13.68
Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol (2008) 11.43
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 10.66
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87
Integrative analysis of the Caenorhabditis elegans genome by the modENCODE project. Science (2010) 9.78
ChIP-seq guidelines and practices of the ENCODE and modENCODE consortia. Genome Res (2012) 9.13
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature (2010) 8.87
Differential chromatin marking of introns and expressed exons by H3K36me3. Nat Genet (2009) 8.11
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 8.11
Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature (2011) 7.43
Model-based analysis of two-color arrays (MA2C). Genome Biol (2007) 7.28
X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell (2006) 7.17
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
Molecular determinants for the tissue specificity of SERMs. Science (2002) 6.20
A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell (2007) 5.99
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res (2007) 5.97
Nucleosome dynamics define transcriptional enhancers. Nat Genet (2010) 5.94
A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic lipid metabolism. Science (2011) 5.91
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest (2010) 5.77
Chromatin structure analyses identify miRNA promoters. Genes Dev (2008) 5.40
Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell (2005) 5.38
High-throughput mapping of the chromatin structure of human promoters. Nat Biotechnol (2007) 5.24
Formation of the androgen receptor transcription complex. Mol Cell (2002) 4.93
PPARgamma and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale. Genes Dev (2008) 4.83
Integrating regulatory motif discovery and genome-wide expression analysis. Proc Natl Acad Sci U S A (2003) 4.74
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res (2012) 4.67
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res (2011) 4.65
Intrinsic histone-DNA interactions are not the major determinant of nucleosome positions in vivo. Nat Struct Mol Biol (2009) 4.64
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. J Clin Invest (2011) 4.41
CEAS: cis-regulatory element annotation system. Bioinformatics (2009) 4.26
Cistrome: an integrative platform for transcriptional regulation studies. Genome Biol (2011) 4.13
Systematic evaluation of variability in ChIP-chip experiments using predefined DNA targets. Genome Res (2008) 4.08
A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A (2008) 3.83
EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science (2012) 3.74
Chromatin marks identify critical cell types for fine mapping complex trait variants. Nat Genet (2012) 3.67
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55
Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci U S A (2011) 3.54
Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem (2004) 3.51
High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell (2004) 3.46
8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc Natl Acad Sci U S A (2010) 3.37
p63 regulates an adhesion programme and cell survival in epithelial cells. Nat Cell Biol (2006) 3.37
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA (2006) 3.32
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol (2009) 3.24
Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med (2012) 3.21
CEAS: cis-regulatory element annotation system. Nucleic Acids Res (2006) 3.15
The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest (2010) 3.09
The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res (2006) 3.07
A hidden Markov model for analyzing ChIP-chip experiments on genome tiling arrays and its application to p53 binding sequences. Bioinformatics (2005) 3.06
Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc Natl Acad Sci U S A (2009) 2.95
Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Cancer Res (2007) 2.95
A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell (2013) 2.94
A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat Biotechnol (2011) 2.91
A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A (2006) 2.89
Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One (2011) 2.88
Differentiation-specific histone modifications reveal dynamic chromatin interactions and partners for the intestinal transcription factor CDX2. Dev Cell (2010) 2.84
Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer. Nat Struct Mol Biol (2013) 2.84
Eukaryotic regulatory element conservation analysis and identification using comparative genomics. Genome Res (2004) 2.84
Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res (2011) 2.81
Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production. Immunity (2012) 2.80
A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Genes Dev (2006) 2.76
Evolutionarily conserved multisubunit RBL2/p130 and E2F4 protein complex represses human cell cycle-dependent genes in quiescence. Mol Cell (2007) 2.74
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
Identifying positioned nucleosomes with epigenetic marks in human from ChIP-Seq. BMC Genomics (2008) 2.66
Chromatin signature of embryonic pluripotency is established during genome activation. Nature (2010) 2.64